Platinum-based chemotherapy is widely used and effective as antineoplastic agents. They are also considered to be potentially highly ototoxic. Effects of platinium-based chemotherapy on hearing loss have been evaluated in childhood cancer patients and survivors but not in adult cancer patients and patients undergoing platinum-based chemotherapy.
We analyzed the clinical data and acute ototoxicity of adult patients with solid cancer receiving platinum-based chemotherapy in Dongnam Institution of Radiological and Medical Sciences(DIRAMS).
This study included 130 patients treated with platinum-based chemotherapy for malignancy in DIRAMS from July 2016 to March 2017. Hearing was assessed by pure tone audiometry (0.25 to 8 kHz) in 0,1,2,3 months after starting platinum. Absolute hearing loss (AHL) was defined as thresholds of > 20 dB at any frequency. AHL was identified in 59 cases (45%) at baseline, 58 cases (45%) at 1month, 38/91 cases (42%) at 2 months and 26/64 cases (41%) at 3 months. The number of patients who received cisplatin, which is more highly ototoxic than other platinum agents, was 78 (60%). In patients receiving cisplatin, AHL was identified in 33 cases (44%) at baseline, 32 cases (41%) at 1 month, 18/50 cases (36%) at 2 months and 14/33 cases (42%) at 3 months. Cumulative cisplatin doses were not associated with hearing loss.
In this study, adult cancer patients undergoing platinum-based chemotherapy have no significant hearing loss. So, acute ototoxicity of platinum was not shown. We do not clearly know when platinuminduced hearing loss will occur. Therefore, long term follow-up of adult cancer patients receiving platinum-based chemotherapy is needed.
Clinical trial identification
Legal entity responsible for the study
All authors have declared no conflicts of interest.